Ignite Creation Date:
2025-12-24 @ 2:53 PM
Ignite Modification Date:
2025-12-27 @ 9:54 PM
Study NCT ID:
NCT06250959
Status:
RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-02-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Sponsor:
Chen Suning
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
BEAT-ALL-2024
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None